Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCTGNASDAQ:CTICNASDAQ:RPHMNASDAQ:SPRBNASDAQ:XERS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTGBCTG Acquisition$10.68$9.83▼$14.00$218.05MN/A36,697 shs2,024 shsCTICCTI BioPharma$9.09$9.06$4.01▼$9.10$1.20B0.834.50 million shsN/ARPHMReneo Pharmaceuticals$1.67+1.2%$1.66$0.98▼$10.98$55.81M0.24271,055 shs115,223 shsSPRBSpruce Biosciences$0.70$2.35$0.67▼$5.95$28.85M2.521.10 million shs194,704 shsXERSXeris Biopharma$1.75+2.9%$2.29$1.46▼$3.26$259.44M2.332.12 million shs861,579 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTGBCTG Acquisition0.00%0.00%0.00%0.00%0.00%CTICCTI BioPharma0.00%0.00%0.00%0.00%+84.01%RPHMReneo Pharmaceuticals-1.79%-6.25%0.00%0.00%-83.45%SPRBSpruce Biosciences-0.11%0.00%+0.14%-79.38%-66.30%XERSXeris Biopharma-3.41%-3.41%-17.07%-31.73%-21.66%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTGBCTG AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACTICCTI BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ARPHMReneo Pharmaceuticals1.7405 of 5 stars2.90.00.00.03.22.51.3SPRBSpruce Biosciences3.8668 of 5 stars4.15.00.00.01.82.51.3XERSXeris Biopharma3.6428 of 5 stars3.52.00.04.20.02.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTGBCTG AcquisitionN/AN/AN/AN/ACTICCTI BioPharma2.00HoldN/AN/ARPHMReneo Pharmaceuticals1.88Reduce$18.14986.08% UpsideSPRBSpruce Biosciences2.25Hold$5.67709.52% UpsideXERSXeris Biopharma3.00Buy$4.88178.57% UpsideCurrent Analyst RatingsLatest XERS, SPRB, RPHM, BCTG, and CTIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024XERSXeris BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/14/2024SPRBSpruce BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $3.003/14/2024SPRBSpruce BiosciencesLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/14/2024SPRBSpruce BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/14/2024SPRBSpruce BiosciencesSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$9.00 ➝ $2.003/14/2024SPRBSpruce BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$9.00 ➝ $2.003/14/2024SPRBSpruce BiosciencesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/14/2024SPRBSpruce BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral3/7/2024XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.50 ➝ $6.003/5/2024SPRBSpruce BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.002/26/2024SPRBSpruce BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $9.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTGBCTG AcquisitionN/AN/AN/AN/A$0.23 per shareN/ACTICCTI BioPharma$53M22.62N/AN/A($0.14) per share-64.93RPHMReneo PharmaceuticalsN/AN/AN/AN/A$2.66 per shareN/ASPRBSpruce Biosciences$10.09M2.86N/AN/A$1.88 per share0.37XERSXeris Biopharma$163.91M1.58N/AN/A($0.05) per share-35.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTGBCTG Acquisition-$120KN/A0.00N/AN/AN/AN/AN/AN/ACTICCTI BioPharma-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/ARPHMReneo Pharmaceuticals-$77.39M-$2.52N/AN/AN/AN/A-73.14%-63.85%5/9/2024 (Estimated)SPRBSpruce Biosciences-$47.92M-$1.25N/AN/AN/A-474.96%-52.31%-39.77%5/20/2024 (Estimated)XERSXeris Biopharma-$62.26M-$0.45N/AN/AN/A-37.98%-610.76%-19.15%5/14/2024 (Estimated)Latest XERS, SPRB, RPHM, BCTG, and CTIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023RPHMReneo Pharmaceuticals-$0.55-$0.70-$0.15-$0.70N/AN/A3/13/2024Q4 2023SPRBSpruce Biosciences-$0.41-$0.23+$0.18-$0.23$1.65 million$2.89 million3/6/2024Q4 2023XERSXeris Biopharma-$0.09-$0.10-$0.01-$0.10$45.50 million$44.39 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTGBCTG AcquisitionN/AN/AN/AN/AN/ACTICCTI BioPharmaN/AN/AN/AN/AN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTGBCTG AcquisitionN/A4.804.80CTICCTI BioPharmaN/A1.271.26RPHMReneo PharmaceuticalsN/A5.875.87SPRBSpruce Biosciences0.024.184.18XERSXeris Biopharma49.271.641.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTGBCTG Acquisition62.44%CTICCTI BioPharma91.45%RPHMReneo Pharmaceuticals90.98%SPRBSpruce Biosciences91.71%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipBCTGBCTG AcquisitionN/ACTICCTI BioPharma7.61%RPHMReneo Pharmaceuticals17.90%SPRBSpruce Biosciences9.10%XERSXeris Biopharma4.36%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCTGBCTG AcquisitionN/A21.38 millionN/ANot OptionableCTICCTI BioPharma127131.88 million121.84 millionOptionableRPHMReneo Pharmaceuticals833.42 million27.44 millionOptionableSPRBSpruce Biosciences2941.15 million37.41 millionOptionableXERSXeris Biopharma377148.25 million134.33 millionOptionableXERS, SPRB, RPHM, BCTG, and CTIC HeadlinesSourceHeadlineXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutionsfinance.yahoo.com - April 5 at 12:23 PMXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)finance.yahoo.com - April 3 at 6:23 PMXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - April 2 at 8:50 AMXeris Biopharma (NASDAQ:XERS) Now Covered by Oppenheimermarketbeat.com - March 28 at 8:29 AMXeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 Growthproactiveinvestors.com - March 18 at 9:49 PMHere's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Resultsfinance.yahoo.com - March 9 at 1:59 PMXeris Biopharma (XERS) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 8 at 7:43 PMXeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023finance.yahoo.com - March 7 at 2:41 PMXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 7 at 1:01 PMQ4 2023 Xeris Biopharma Holdings Inc Earnings Callfinance.yahoo.com - March 7 at 12:19 AMXeris Biopharma Shares Drop After Weak 4Q Resultsmarketwatch.com - March 6 at 7:18 PMXeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84Mmsn.com - March 6 at 7:18 PMXERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023investorplace.com - March 6 at 2:00 PMXeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jumpproactiveinvestors.com - March 6 at 9:57 AMXeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimateszacks.com - March 6 at 9:16 AMXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Eventsbusinesswire.com - March 6 at 7:02 AMXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capitalbusinesswire.com - March 6 at 7:00 AMWhy Xeris (XERS) Might Surprise This Earnings Seasonzacks.com - March 5 at 10:46 AMXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024businesswire.com - February 28 at 7:00 AM3 Breakout Stocks Under $5 to Buy for More Upsidetheglobeandmail.com - February 23 at 7:13 PMXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conferencefinance.yahoo.com - February 5 at 9:27 AMBig Game or Small, Here's How to Go About Stalking a Traderealmoney.thestreet.com - February 3 at 6:45 PMXeris inks licensing deal with Amgen on former Horizon drugchicagobusiness.com - January 12 at 9:32 AMXeris Biopharma jumps on news of Amgen dealthepharmaletter.com - January 12 at 9:32 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBCTG AcquisitionNASDAQ:BCTGBCTG Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses primarily located in North America and Europe in the biotechnology industry. The company was incorporated in 2020 and is based in San Diego, California.CTI BioPharmaNASDAQ:CTICCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Reneo PharmaceuticalsNASDAQ:RPHMReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.Spruce BiosciencesNASDAQ:SPRBSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Xeris BiopharmaNASDAQ:XERSXeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.